top of page

Disclaimer: All products are for laboratory research only and not for human or animal use or consumption. For in-vitro research by qualified professionals only

Crystagen

Crystagen

$49.99Price
Quantity
Quantity

Purchase Crystagen Research Peptide

Crystagen is a synthetic tetrapeptide extensively studied in ophthalmology and aging research for its role as a selective modulator of ocular tissue gene expression and retinal homeostasis. This bioregulatory peptide serves as a critical research tool for investigating photoreceptor survival mechanisms, age-related retinal degeneration pathways, and ocular tissue repair in preclinical models.

Crystagen Identity & Structural Overview

Crystagen (Lys-Glu-Asp-Pro) is a four-amino acid bioregulatory peptide belonging to the class of short peptide bioregulators developed through cytomax peptide isolation methodology. Its compact tetrapeptide architecture enables favorable cellular penetration properties and selective chromatin binding affinity documented in preclinical pharmacological studies. The lysine residue at the N-terminal position contributes a positively charged amino group that facilitates nuclear chromatin interaction, while the C-terminal proline confers structural rigidity and enhanced resistance to nonspecific peptidase degradation in biological assay systems.

Mechanism of Action

Preclinical research demonstrates that Crystagen exerts its cytoprotective effects through direct interaction with retinal cell chromatin, selectively modulating transcriptional activity of genes governing photoreceptor differentiation, müller glial support cell function, and retinal pigment epithelium homeostasis. Studies have documented its capacity to stimulate retinal progenitor cell activity, enhance expression of ocular neurotrophic factors including BDNF and CNTF, attenuate oxidative stress-induced photoreceptor apoptotic signaling, and normalize age-related disruptions in retinal gene expression profiles in isolated ocular tissue preparations and intact animal models.

Key Research Findings

Foundational research by Khavinson et al. established Crystagen as a retinoselective bioregulatory peptide through nuclear chromatin binding studies, demonstrating preferential affinity for retinal cell nuclear fractions compared to non-ocular tissue preparations. Subsequent preclinical investigations documented Crystagen-mediated preservation of photoreceptor density and retinal layer architecture in light-induced degeneration and age-related retinal deterioration animal models, with observed improvements in electroretinographic response parameters, restoration of retinal pigment epithelium integrity markers, and normalization of oxidative stress indices in treated retinal tissue preparations compared to untreated age-matched controls.

Product Specifications

  • Form: Lyophilized powder (synthetic, high-purity)

  • Sequence: Lys-Glu-Asp-Pro

  • Amino Acid Composition: 4 amino acids

  • Molecular Weight: 471.5 Da

  • Quantity: Single-vial format

  • Storage: −20°C; unopened shelf life of 24 months

  • Reconstitution: Sterile water or bacteriostatic saline

  • Purity: >95% (HPLC verified); endotoxin <1 EU/μg

Research Use Only

For preclinical research purposes only. Not intended for human or veterinary use. All handling must adhere to institutional biosafety committee guidelines.

    bottom of page